Parabilis Medicines Management
Management criteria checks 2/4
We currently do not have sufficient information about the CEO.
Key information
Mathai Mammen
Chief executive officer
US$1.3m
Total compensation
| CEO salary percentage | 60.59% |
| CEO tenure | 3yrs |
| CEO ownership | n/a |
| Management average tenure | 1.8yrs |
| Board average tenure | 3.6yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | -US$210m |
| Dec 31 2025 | US$1m | US$785k | -US$187m |
Compensation vs Market: Mathai's total compensation ($USD1.30M) is below average for companies of similar size in the US market ($USD5.30M).
Compensation vs Earnings: Insufficient data to compare Mathai's compensation with company performance.
CEO
Mathai Mammen (59 yo)
Dr. Mathai Mammen, M.D., Ph D., serves as Senior Advisor at Advisors. Dr. Mammen is Senior Advisor of General Atlantic Service Company, L.P. from April 25, 2023, where he provides strategic counsel and adv...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President | 3yrs | US$1.30m | no data | |
| Executive VP | 1.8yrs | US$691.59k | 0% $ 0 | |
| Chief Medical Officer | less than a year | US$1.08m | 0% $ 0 | |
| Scientific Co-Founder | no data | no data | no data | |
| Chief Financial Officer | 4.5yrs | no data | 0% $ 0 | |
| Chief Technical Operations Officer | 2.7yrs | no data | 0% $ 0 | |
| VP of International R&D and Corporate Development | less than a year | no data | no data | |
| Chief People Officer | 3.4yrs | no data | no data | |
| Executive Vice President of Discovery Biology | 5.5yrs | no data | no data | |
| Senior VP & Head of Clinical Development | 1.4yrs | no data | no data | |
| Executive Vice President of Discovery Science | 1.4yrs | no data | no data | |
| Chief Business & Strategy Officer | less than a year | no data | no data |
Experienced Management: PBLS's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President | 3yrs | US$1.30m | no data | |
| Independent Non-Employee Director | 8.9yrs | US$80.00k | 0% $ 0 | |
| Independent Non-Employee Director | less than a year | no data | no data | |
| Independent Non-Employee Director | 2.3yrs | no data | no data | |
| Independent Non-Employee Director | 3.6yrs | US$20.00k | 0% $ 0 | |
| Member of Scientific Advisory Board | 4.4yrs | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Non-Employee Director | 8.2yrs | no data | no data | |
| Independent Non-Employee Director | 7.7yrs | US$80.00k | 0% $ 0 | |
| Independent Non-Employee Director | less than a year | no data | no data |
Experienced Board: PBLS's board of directors are considered experienced (3.6 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/06/10 05:59 |
| End of Day Share Price | 2026/06/10 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Parabilis Medicines, Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.